Jafron Biomedical Co

Jafron Biomedical Co Net Change in Cash

The Net Change in Cash of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 799.32 M CNY. In the previous year, Net Change in Cash was -1.07 B CNY — a change of -174.99% (higher).

Net Change in Cash

799.32 MCNY

YoY

-174.99%

Last updated:

Net Change in Cash of Jafron Biomedical Co is 2025 799.32 M CNY. Net Change in Cash of Jafron Biomedical Co was 2024 -1.07 B CNY. It decreases by -174.99% higher compared to the previous year.

The Jafron Biomedical Co Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
14.64 M CNY
Jan 1, 2019
190.93 M CNY
Jan 1, 2020
303.32 M CNY
Jan 1, 2021
744.37 M CNY
Jan 1, 2022
211.93 M CNY
Jan 1, 2023
215.19 M CNY
Jan 1, 2024
-1.07 B CNY
Jan 1, 2025
799.32 M CNY
The Jafron Biomedical Co Net Change in Cash history
YEARNet Change in CashYoY
799.32 MCNY-174.99%
-1.07 BCNY-595.31%
215.19 MCNY+1.54%
211.93 MCNY-71.53%
744.37 MCNY+145.41%
303.32 MCNY+58.87%
190.93 MCNY+1,203.83%
14.64 MCNY-95.14%
301.07 MCNY-36.32%
472.76 MCNY+767.81%
54.48 MCNY-451.04%
-15.52 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Net Change in Cash of Jafron Biomedical Co is 799.32 M CNY in 2025.

Net Change in Cash of Jafron Biomedical Co changed from -1.07 B CNY to 799.32 M CNY, representing a -174.99% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co